Background: The RhD antigen is the most polymorphic and immunogenic red cell determinant. In clinical practice, Weak D, Partial D, and DEL variants exhibit weakened or discrepant serological reactivities, hindering the accurate determination of Rh status. Aim: To evaluate the contribution and accuracy of RHD genotyping in resolving serological anomalies of the RhD antigen, defining the epidemiological distribution of variants, concordance with serological profiles, and the impact on transfusion and obstetric management. Materials and Methods: A total of 550 samples (blood donors and patients) referred to the Transfusion Medicine Service of ULSS 3 Serenissima (Dell’Angelo Hospital, Mestre) were analysed. Samples were selected based on weak direct agglutination (score ≤ 3+), discrepancies between monoclonal antisera, or positive results in the weak D test by indirect antiglobulin. Molecular typing was performed using the BioArray RHD BeadChip microarray platform. Molecular findings were correlated with the Rh phenotype (C, c, E, e), agglutination scores from three monoclonal anti-D reagents in column agglutination technology (Clone 1: MS-201; Clone 2: P3x61 + ESD-1M; Clone 3: RUM-1 + ESD-1M), the weak D test in the antiglobulin phase, and anti-D immunization status. Results: Genomic analysis identified 394 Weak D genotypes (71.64%), 41 Partial D (7.45%), 37 complete RHD deletions (6.73%), 1 DEL (0.18%), and 77 Possible D (14.00%). Weak D types 1 (45.45%), 2 (7.64%), and 3 (4.00%) collectively accounted for 57.09% of the cohort. A clear haplotypic segregation with the RhCE system was observed: Weak D types 1, 3, and 11 were 100% associated with the C antigen (p ≤ 0.003; Ccee phenotype), whereas Weak D types 2 and 15 strongly correlated with the E antigen (p < 0.001; ccEe phenotype). Serological reactivity profiles revealed intrinsic limitations: while Clone 1 effectively discriminated the DVI variant (100% negative), it yielded indistinguishable agglutination scores (modal score 3+) between clinically safe variants (Weak D type 1) and variants carrying a risk of alloimmunization (Weak D type 4.0/4.3). Importantly, among the 314 subjects carrying Weak D types 1, 2, and 3, no cases of active primary anti-D alloimmunization were detected. Conclusions: Molecular RHD genotyping proves to be an indispensable and complementary tool to serology. By reclassifying over 57% of investigated subjects (Weak D types 1, 2, or 3) as D-positive, this integrated diagnostic algorithm preserves D-negative red blood cell inventories and avoids inappropriate administration of anti-D immunoprophylaxis in pregnant women, ensuring optimal transfusion and obstetric safety.
Introduzione: L’antigene RhD è il determinante eritrocitario più polimorfo e immunogeno. Nella pratica clinica, le varianti Weak D, Partial D e DEL manifestano reattività sierologiche attenuate o discordanti, rendendo difficoltosa la corretta assegnazione dello status Rh. Scopo: Valutare il contributo e l’accuratezza della genotipizzazione del gene RHD nella risoluzione delle anomalie sierologiche dell’antigene RhD, definendo la distribuzione epidemiologica delle varianti, la concordanza con i profili sierologici e l’impatto sulla gestione trasfusionale e ostetrica. Materiali e Metodi: Sono stati analizzati 550 campioni (donatori di sangue e pazienti) afferenti al Servizio di Medicina Trasfusionale dell’ULSS 3 Serenissima (Ospedale dell’Angelo di Mestre), selezionati in base a reattività debole (score ≤ 3+), discrepanza tra antisieri monoclonali o positività al test per la ricerca del D debole in antiglobulina. La tipizzazione molecolare è stata condotta mediante tecnologia microarray BioArray RHD BeadChip. I dati molecolari sono stati correlati con il fenotipo Rh esteso (C, c, E, e), con gli score dei tre Ab monoclonali anti-D in colonna di gel (Clone 1: MS-201; Clone 2: P3x61 + ESD-1M; Clone 3: RUM-1 + ESD-1M), con il test del D debole in antiglobulina e con lo stato anticorpale anti-D. Risultati: L’indagine genomica ha identificato 394 genotipi a fenotipo D debole (71,64%), 41 D parziali (7,45%), 37 delezioni complete di RHD (6,73%), 1 DEL (0,18%) e 77 Possible D (14,00%). I genotipi Weak D type 1 (45,45%), type 2 (7,64%) e type 3 (4,00%) hanno costituito complessivamente il 57,09% della coorte. È emersa una netta segregazione aplotipica con il sistema RhCE: i Weak D type 1, type 3 e type 11 sono risultati associati al 100% all’antigene C (p ≤ 0,003; fenotipo Ccee), mentre i Weak D type 2 e type 15 hanno correlato fortemente per l’antigene E (p < 0,001; fenotipo ccEe). Il profilo di reattività sierologica ha evidenziato limiti intrinseci: pur confermando l’efficacia del Clone 1 nel discriminare la variante DVI (100% negativi), ha prodotto score di agglutinazione indistinguibili (score modale 3+) tra varianti clinicamente sicure (Weak D type 1) e forme a potenziale rischio alloimmune ( Weak D type 4.0/4.3). Nei 314 soggetti con Weak D type 1, type 2 e type 3 non è stato riscontrato alcun caso di alloimmunizzazione anti-D attiva. Conclusioni: La genotipizzazione molecolare di RHD si conferma uno strumento indispensabile e complementare alla sierologia. Riclassificando come D-positivi oltre il 57% dei soggetti esaminati (Weak D type 1, type 2 o type 3), l’algoritmo diagnostico integrato consente di preservare le scorte di emazie D-negative ed evita la somministrazione inappropriata dell’immunoprofilassi anti-D nelle gestanti, garantendo la massima sicurezza trasfusionale e ostetrica.
Genotipizzazione del gene RHD nella caratterizzazione dei fenotipi varianti e deboli dell'antigene RhD: esperienza del Laboratorio di Immunoematologia dell'ULSS 3 Serenissima del Veneto su una coorte di 550 campioni
PULLIERO, AURORA
2025/2026
Abstract
Background: The RhD antigen is the most polymorphic and immunogenic red cell determinant. In clinical practice, Weak D, Partial D, and DEL variants exhibit weakened or discrepant serological reactivities, hindering the accurate determination of Rh status. Aim: To evaluate the contribution and accuracy of RHD genotyping in resolving serological anomalies of the RhD antigen, defining the epidemiological distribution of variants, concordance with serological profiles, and the impact on transfusion and obstetric management. Materials and Methods: A total of 550 samples (blood donors and patients) referred to the Transfusion Medicine Service of ULSS 3 Serenissima (Dell’Angelo Hospital, Mestre) were analysed. Samples were selected based on weak direct agglutination (score ≤ 3+), discrepancies between monoclonal antisera, or positive results in the weak D test by indirect antiglobulin. Molecular typing was performed using the BioArray RHD BeadChip microarray platform. Molecular findings were correlated with the Rh phenotype (C, c, E, e), agglutination scores from three monoclonal anti-D reagents in column agglutination technology (Clone 1: MS-201; Clone 2: P3x61 + ESD-1M; Clone 3: RUM-1 + ESD-1M), the weak D test in the antiglobulin phase, and anti-D immunization status. Results: Genomic analysis identified 394 Weak D genotypes (71.64%), 41 Partial D (7.45%), 37 complete RHD deletions (6.73%), 1 DEL (0.18%), and 77 Possible D (14.00%). Weak D types 1 (45.45%), 2 (7.64%), and 3 (4.00%) collectively accounted for 57.09% of the cohort. A clear haplotypic segregation with the RhCE system was observed: Weak D types 1, 3, and 11 were 100% associated with the C antigen (p ≤ 0.003; Ccee phenotype), whereas Weak D types 2 and 15 strongly correlated with the E antigen (p < 0.001; ccEe phenotype). Serological reactivity profiles revealed intrinsic limitations: while Clone 1 effectively discriminated the DVI variant (100% negative), it yielded indistinguishable agglutination scores (modal score 3+) between clinically safe variants (Weak D type 1) and variants carrying a risk of alloimmunization (Weak D type 4.0/4.3). Importantly, among the 314 subjects carrying Weak D types 1, 2, and 3, no cases of active primary anti-D alloimmunization were detected. Conclusions: Molecular RHD genotyping proves to be an indispensable and complementary tool to serology. By reclassifying over 57% of investigated subjects (Weak D types 1, 2, or 3) as D-positive, this integrated diagnostic algorithm preserves D-negative red blood cell inventories and avoids inappropriate administration of anti-D immunoprophylaxis in pregnant women, ensuring optimal transfusion and obstetric safety.| File | Dimensione | Formato | |
|---|---|---|---|
|
Pulliero Aurora 2113172.pdf
Accesso riservato
Dimensione
6.62 MB
Formato
Adobe PDF
|
6.62 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/119270